Clinical Scorecard: Molecular Diagnostics for Pathogen Detection in Culture-Negative Endocarditis

At a Glance

Key Highlights

• Blood cultures do not identify a pathogen in an estimated 2.5% to 31% of endocarditis cases, with estimates varying by population and prior antibiotic exposure.
• The 2023 Duke–International Society for Cardiovascular Infectious Diseases criteria added molecular methods to major microbiological criteria, including PCR for selected organisms, amplicon sequencing, and metagenomic sequencing.
• In a prospective study, mcfDNA remained positive for a median of approximately 38 days after antibiotics began, compared with 3.7 days for blood cultures.
• In a retrospective cohort of 141 patients evaluated for suspected endocarditis, mcfDNA detected a pathogen in 60.6% of confirmed cases; it was the sole positive microbiological test in one third of those cases.
• Molecular tests have limitations, including clinically insignificant detections, lack of phenotypic susceptibility information for mcfDNA, cost, restricted availability, and contamination concerns for 16S-based methods.

Guideline-Based Recommendations

Diagnosis

Management

• Interpret mcfDNA results in clinical context; the American Heart Association’s 2025 statement reports no consensus cutoff for clinical significance and advises that microbial abundance alone should not direct clinical decisions.

Monitoring & Follow-up

• The Karius test generally returns findings within 24 to 28 hours and reports quantitative results as molecules per microliter of plasma.
• mcfDNA may remain detectable longer than blood cultures after antibiotic initiation; the cited prospective study reported median positivity of approximately 38 days versus 3.7 days.

Risks

• Approximately 29% of patients who ultimately lack an endocarditis diagnosis had clinically insignificant mcfDNA detections in the cited study.
• mcfDNA does not provide phenotypic antimicrobial susceptibility information, entails substantial cost, and is available through only one reference laboratory, according to the article.
• 16S-based methods have lower sensitivity in blood than tissue and persistent contamination concerns.

Patient & Prescribing Data

Patients with suspected endocarditis and negative cultures, including those with prior antibiotic exposure or possible fastidious or intracellular pathogens.

In the cited retrospective cohort, mcfDNA sequencing detected a pathogen in 60.6% of confirmed cases; in one third of those cases it was the sole positive microbiological test, and antimicrobial therapy was modified in half of that subgroup.

Clinical Best Practices

• Consider molecular diagnostics as a complement to conventional microbiology when evaluating suspected culture-negative endocarditis.
• Interpret mcfDNA detections alongside the clinical presentation and other diagnostic findings; do not use microbial abundance alone to direct decisions.
• Recognize that mcfDNA can detect pathogens without a prespecified organism hypothesis; 16S rRNA gene methods target bacteria.
• Account for the possibility of clinically insignificant detections and contamination when interpreting molecular results.

Related Resources & Content